Perrigo Company (NASDAQ:PRGO) recently received some good news when the U.S. Food and Drug Administration (FDA) cleared its generic version of Novartis’ (NYSE:NVS) heart burn drug Prevacid. Approval was granted to treat patients suffering from frequent heartburn (two or more days in a week).
Perrigo launched the drug in the U.S.  following the receipt of final approval from the U.S.  regulatory body of the abbreviated new drug application (ANDA) filed by Perrigo seeking approval to market … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards